Human PD-L1-expressing Raji Cells

Human PD-L1-expressing B cells

Raji-hPD-L1 cells were developed from the Raji cell line, a human B lymphocyte-derived cell line. Raji cells have been successfully used as target cells in CAR-T toxicity assays as well as in human effector studies such as antibody-dependent cellular cytotoxicity (ADCC), either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells.

PD-L1 (programmed cell death ligand 1; also known as CD274 or B7-H1) is a transmembrane protein expressed at the cell surface of hematopoietic and nonhematopoietic cells and is induced by pro-inflammatory cytokines, such as in the tumor microenvironment [1]. PD-L1 is one ligand for PD-1, an inhibitory immune checkpoint receptor that is expressed by activated and exhausted T cells. PD-1:PD-L1 interaction induces inhibition of T-cell receptor signaling, thereby preventing T-cell overstimulation and host damage [1].

Features of Raji-hPD-L1 cells:

• Stable overexpression of the human PD-L1 gene
• Characterized by a number of cell-surface expressed markers including the B cell receptor (BCR), CD19, and CD20
• Constitutive expression of various immune checkpoints (ICs) such as CD27, CD70, CD80, PD-L1, and 4-1BBL
• The stability for 20 passages following thawing has been verified

Applications for Raji-hPD-L1 cells:

• Target cell line for ADCC assays using InvivoGen's Jurkat-Lucia™ NFAT-CD16 cells
• Target cell line for cell toxicity assays using NK or CAR-T cells
• For use in the development of other functional assays

Validation of Raji-hPD-L1 cells:

• Overexpression of PD-L1 verified by flow cytometry
• Functionally tested as target cells in ADCC assays using anti-human PD-L1 monoclonal Abs  and Jurkat-Lucia™ NFAT-CD16 cells
• Guaranteed mycoplasma-free

References:

1. Ribas A. and Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.